JACC: BASIC TO TRANSLATIONAL SCIENCE VOL. 1, NO. 5, 2016

ISSN 2452-302X
http://dx.doi.org/10.1016/j.jacbts.2016.05.006

EDITORIAL COMMENT

Direct Effects of Activation and Inhibition of the Coagulation System on the Atrial Fibrillation Substrate

Is Anticoagulation Antiarrhythmic?*

Stanley Nattel, MD

Atrial fibrillation (AF) is a highly prevalent clinical problem that is becoming more common with population aging, and presents a broad range of therapeutic challenges (1,2). An improved understanding of the underlying pathophysiology is central to improving management options for the arrhythmia (3).

The most significant complication of AF is thromboembolism, particularly stroke (4). AF-related stroke is effectively prevented by oral anticoagulation (OAC), achieved traditionally by vitamin K antagonists (VKAs) such as warfarin, and more recently by direct-acting agents (DOACs) such as the thrombin-antagonist dabigatran and the Factor Xa (FXa) inhibitors rivaroxaban, apixaban, and edoxaban (4). Because of the attendant bleeding risk, OAC therapy has been targeted to patients with elevated stroke risk, although with the reduced bleeding seen with DOACs versus VKAs, the threshold for OAC therapy has decreased and the emphasis has shifted to identifying true low-risk individuals who may safely be managed without OAC (5).

It has long been known that thrombin possesses proinflammatory effects mediated by protease-activated receptor (PAR)-1 (6) and that both thrombin and FXa have profibrotic effects (7). Furthermore, thrombin-inhibition has antifibrotic effects (8). Atrial fibrosis is a major potential contributor to the substrate for AF maintenance (9,10), and therefore beyond its role in clotting, activated thrombin or FXa could contribute to the progression of the AF substrate. Conversely, inhibitors of thrombin or FXa such as the DOACs could have an AF-suppressing effect.

THROMBIN INHIBITION AND THE AF SUBSTRATE IN A RAT MODEL OF CARDIAC DYSFUNCTION

In this issue of *JACC: Basic to Translational Science*, Jumeau et al. (11) study the role of thrombin signaling in a rat model of cardiac dysfunction due to myocardial infarction (MI) (11). MI was created by ligating the left anterior descending coronary artery for 30 min, followed by reperfusion. MI caused ventricular dysfunction, enhanced thrombogenesis, atrial fibrosis and dilation, and an AF substrate (the duration of

SEE PAGE 328

induced AF increased from approximately 3 s to approximately 6 s, $p = 0.02$) over a period of 4 weeks to 8 weeks. Dabigatran or another direct-acting thrombin inhibitor (DTI) suppressed these changes, while attenuating the upregulation of a variety of remodeling-related (connective tissue growth factor [CTGF], brain natriuretic peptide [BNP], α-myosin heavy chain [MHC]) and procoagulant (plasminogen activator inhibitor [PAI]-1) factors/biomarkers. The direct effects of thrombin were studied in rat atrial explants, showing that it increases the expression of BNP, α-MHC, PAI-1, and phosphorylated signal

*Editorials published in *JACC: Basic to Translational Science* reflect the views of the authors and do not necessarily represent the views of *JACC: Basic to Translational Science* or the American College of Cardiology.

From the Department of Medicine, Montreal Heart Institute and Université de Montréal, Montréal, Canada; Department of Pharmacology and Therapeutics, McGill University, Montreal, Canada; and the Institute of Pharmacology, West German Heart and Vascular Center, Faculty of Medicine, University Duisburg-Essen, Essen, Germany. Dr. Nattel has reported that he has no relationships relevant to the contents of this paper to disclose.

TABLE 1 Summary of Studies Addressing the Role of Thrombin Activation and Anticoagulation in Atrial Electrophysiology and AF-Promoting Remodeling

First Author, Year (Ref. #)	Tissue	Experiment	Biochemical Effect(s)	Remodeling Effects	Electrophysiological Effect(s)
Bukowska, 2013 (15)	Human atrium	Exposure to Fxa	Upregulation of PAR2, ICAM-1, IL-8, PAI-1	NT	NT
		Tachypacing + Fxa	Upregulation PAR1/2, ICAM-1, IL-8, PAI-1, LOX-1	NT	NT
		Fxa/TP + RIVA or PAR1-blocker	Effects blocked by RIVA	NT	NT
Chang, 2012 (12)	Rabbit PV	Exposure in vitro	NT	NT	Thrombin decreased PV automaticity and APD L-NAME, dabigatran or PAR-1 blocker attenuated effects
Chang, 2013 (14)	Rabbit LA	LA cells in vitro	NT	NT	RIVA decreased APD and increased diastolic tension RIVA increased $I_{Ca,L}$ and I_{Kur}, no change in I_{to}
Spronk, 2016 (16)	Rat atrial FBs	Exposure in vitro	Thrombin ↑P-Akt, pERK, TGFβ, MCP1 expression Thrombin enhanced ^{3}H-proline incorporation Effects blocked by dabigatran and PAR1 inhibitor		
	TG mice	Procoagulant mice	Atrial fibrosis	Atrial fibrosis	Increased AF inducibility and duration
	AF goats	Nadroparin		Decreased Fibrosis, αSMA positive FBs	Decreased complexity of AF; AFCL unchanged; ?AF duration
Jumeau, 2016 (11)	MI rats	DTI or PAR1 blocker therapy	DTI suppressed CTGF, PAI-1 upregulation DTI decreased BNP, αMHC upregulation	DTI or PAR1 decreased LA size DTI decreased LA fibrosis, hypertrophy	AF promotion suppressed
	Rat atria	Thrombin, PAR1, ROCK blocker	Thrombin increased BNP, αMHC, PAI-1, pSTAT3 Thrombin effect blocked by PAR1, ROCK blocker		

AF = atrial fibrillation; APD = action potential duration; BNP = brain natriuretic peptide; DTI = direct thrombin inhibitor; FB = fibroblast; FXa = Factor Xa; $I_{Ca,L}$ = L-type Ca^{2+} current; ICAM = intracellular adhesion molecule; I_{Kur} = ultrarapid delayed rectifier K^{+} current; IL = interleukin; I_{to} = transient outward K^{+} current; LA = left atrium; L-NAME = N(G)-nitro-L-arginine methyl ester; LOX = lysyl oxidase; MCP = monocyte chemoattractant protein; αMHC = α myosin heavy chain; NT = not tested; PAI = plasminogen activator inhibitor; pAkt = phosphorylated Akt; PAR = protease-activated receptor; pERK = phosphorylated extracellular signal-related kinase; pSTAT3 = phosphorylated STAT3; PV = pulmonary vein; RIVA = rivaroxaban; ROCK = Rho-associated coiled-coil kinase; SMA = smooth muscle actin; TGF = transforming growth factor; TG = transgenic; TP = tachypacing.

transducer and activator of transcription-3, or STAT3 (pSTAT3), and that these effects are prevented by a PAR-1 blocker and an inhibitor of Rho coiled-coil kinase (ROCK) signaling. These results indicate a contribution of activated thrombin to profibrillatory atrial remodeling post-MI and suggest that in addition to their anticoagulant effects DTIs may attenuate the development of an AF-supporting substrate.

RELATIONSHIP TO OTHER STUDIES IN THE LITERATURE

A range of other investigators have addressed the effects of OACs on atrial electrophysiology and remodeling, as summarized in Table 1. Chang et al. (12) showed that thrombin decreases pulmonary vein (PV) cellular automaticity and left-atrial (LA) action potential duration (APD) while increasing PV triggered activity, effects that were blocked by dabigatran, a PAR-1 blocker and N(G)-nitro-L-arginine methyl ester (L-NAME) (a nitric oxide synthase inhibitor). An APD reduction should promote re-entry circuits that maintain AF, whereas increased triggered activity should enhance spontaneous AF-initiation (13). In a follow-up study, the same investigators showed that rivaroxaban reduces LA APD in rabbit LA-cells, while increasing L-type Ca^{2+} current and ultrarapid delayed rectifier K^{+} current (14). If applicable to man, these results would suggest that thrombin promotes AF, an effect that can be prevented by a DTI, but that rivaroxaban might be profibrillatory. Bukowska et al. (15) showed that FXa causes proinflammatory signaling in human atrial tissue, upregulating PAR2, phosphorylated extracellular signal-related kinase, intracellular adhesion molecule (ICAM)-1, interleukin-8, and PAI-1. These effects were enhanced by atrial tachypacing to mimic the remodeling effects of AF and suppressed by PAR-1